Nicholas Donoghoe, EVP, CHIEF BUS/STRAT OFFICER of AbbVie Inc (ABBV, Financial), has sold 2,912 shares of the company on December 26, 2023, according to a recent SEC Filing. AbbVie Inc is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's portfolio includes significant products that address cancers, immune disorders, women's health, and chronic neurological conditions.
The insider's transaction history indicates that over the past year, the insider has sold a total of 2,912 shares and has not made any purchases of the company's stock.
The insider transaction history for AbbVie Inc shows a pattern of insider activity. Over the past year, there have been no insider buys and 17 insider sells.
On the day of the insider's recent sell, shares of AbbVie Inc were trading at $154.72, giving the company a market capitalization of $273.61 billion.
The price-earnings ratio of AbbVie Inc stands at 42.46, which is above the industry median of 24.115 and also exceeds the company's historical median price-earnings ratio.
With the current share price of $154.72 and a GuruFocus Value of $133.72, AbbVie Inc has a price-to-GF-Value ratio of 1.16, indicating that the stock is considered Modestly Overvalued according to the GF Value metric.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated based on historical trading multiples, a GuruFocus adjustment factor related to the company's past performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
